A Double-Blind, Randomized Phase II Study of Dicycloplatin Plus Paclitaxel Versus Carboplatin Plus Paclitaxel As First-Line Therapy for Patients with Advanced Non-Small-cell Lung Cancers.
Ke-Jun Liu,Zhong-Zhen Guan,Ying Liang,Xu-Qing Yang,Jin Peng,He Huang,Qing-Xiang Shao,Meng-Zhao Wang,Yun-Zhong Zhu,Chang-Ping Wu,Shao-Bin Wang,Jian-Ping Xiong,Yu-Xian Bai,Shi-Ying Yu,Yang Zhang,Xiao-Hua Hu,Feng,Shi-Xiu Wu,Shun-Chang Jiao,Cai-Cun Zhou,Jie Wang,Hai-Ying Wu
DOI: https://doi.org/10.5114/aoms.2014.44862
2014-01-01
Abstract:INTRODUCTION:The aim of this study was to compare the efficacy and toxicity of dicycloplatin plus paclitaxel with those of carboplatin plus paclitaxel as first-line treatment for patients with advanced non-small-cell lung cancer (NSCLC).MATERIAL AND METHODS:In this study, 240 NSCLC patients with stage IIIB (with pleural effusion) and stage IV disease were randomly assigned (1: 1) to receive dicycloplatin 450 mg/m(2) or carboplatin AUC = 5, in combination with paclitaxel 175 mg/m(2) (D + P or C + P) every 3 weeks for up to 4 to 6 cycles. The primary endpoint was response rate. Secondary endpoints included progression-free survival (PFS), overall survival (OS) and adverse events.RESULTS:The response rates for the D + P and C + P arm were 36.44% and 30.51%, respectively (p = 0.33). The median PFS was 5.6 months in the D + P arm and 4.7 months in the C + P arm (p = 0.31). The median OS was 14.9 months for D + P and 12.9 months for C + P (p = 0.37). Adverse events in the two arms were well balanced. The most common grade 3/4 adverse event was hematologic toxicity.CONCLUSIONS:Patients treated with D + P had similar response and survival rates to those treated with C + P, and toxicities of both treatments were generally tolerable.